Integrating transcriptomics, metabolomics, and network pharmacology to investigate multi-target effects of sporoderm-broken spores of <i>Ganoderma lucidum</i> on improving HFD-induced diabetic nephropathy rats

Lidan Hu; Lili Yu; Zhongkai Cao; Yue Wang; Caifeng Zhu; Yayu Li; Jiazhen Yin; Zhichao Ma; Xuelin He; Ying Zhang; Wunan Huang; Yuelin Guan; Yue Chen; Xue Li; Xiangjun Chen

doi:10.1016/j.jpha.2024.101105

Volume 14 Issue 12

Dec. 2024

Turn off MathJax

Article Contents

Article Navigation > Journal of Pharmaceutical Analysis > 2024 > 14(12): 101105

Lidan Hu, Lili Yu, Zhongkai Cao, Yue Wang, Caifeng Zhu, Yayu Li, Jiazhen Yin, Zhichao Ma, Xuelin He, Ying Zhang, Wunan Huang, Yuelin Guan, Yue Chen, Xue Li, Xiangjun Chen. Integrating transcriptomics, metabolomics, and network pharmacology to investigate multi-target effects of sporoderm-broken spores of Ganoderma lucidum on improving HFD-induced diabetic nephropathy rats[J]. Journal of Pharmaceutical Analysis, 2024, 14(12): 101105. doi: 10.1016/j.jpha.2024.101105

Citation:

Lidan Hu, Lili Yu, Zhongkai Cao, Yue Wang, Caifeng Zhu, Yayu Li, Jiazhen Yin, Zhichao Ma, Xuelin He, Ying Zhang, Wunan Huang, Yuelin Guan, Yue Chen, Xue Li, Xiangjun Chen. Integrating transcriptomics, metabolomics, and network pharmacology to investigate multi-target effects of sporoderm-broken spores of Ganoderma lucidum on improving HFD-induced diabetic nephropathy rats[J]. Journal of Pharmaceutical Analysis, 2024, 14(12): 101105. doi: 10.1016/j.jpha.2024.101105

Citation:

Lidan Hu, Lili Yu, Zhongkai Cao, Yue Wang, Caifeng Zhu, Yayu Li, Jiazhen Yin, Zhichao Ma, Xuelin He, Ying Zhang, Wunan Huang, Yuelin Guan, Yue Chen, Xue Li, Xiangjun Chen. Integrating transcriptomics, metabolomics, and network pharmacology to investigate multi-target effects of sporoderm-broken spores of Ganoderma lucidum on improving HFD-induced diabetic nephropathy rats[J]. Journal of Pharmaceutical Analysis, 2024, 14(12): 101105. doi: 10.1016/j.jpha.2024.101105

PDF( 6848 KB)

Integrating transcriptomics, metabolomics, and network pharmacology to investigate multi-target effects of sporoderm-broken spores of Ganoderma lucidum on improving HFD-induced diabetic nephropathy rats

doi: 10.1016/j.jpha.2024.101105

a. Department of Nephrology, The Children's Hospital, Zhejiang University School of Medicine, National Clinical Research Center for Child Health, Hangzhou, 310003, China;
b. Centre for Global Health, Usher Institute, The University of Edinburgh, Edinburgh, EH16 4UX, UK;
c. Department of Big Data in Health Science School of Public Health, Zhejiang University School of Medicine, Hangzhou, 310058, China;
d. Hubei Normal University, Huangshi, Hubei, 435002, China;
e. Department of Nephrology, Hangzhou TCM Hospital, Hangzhou, 310007, China;
f. Kidney Disease Center, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, 310003, China;
g. Institute of Translational Medicine, Zhejiang University School of Medicine, Hangzhou, 310020, China;
h. Department of Urology, The Second Hospital of Tianjin Medical University, Tianjin Institute of Urology, Tianjin, 300211, China

Funds:

This work was supported by the National Natural Science Foundation of China (Grant Nos.: 32271311 and 82200784 to Lidan Hu).

Received Date: Mar. 11, 2024
Accepted Date: Sep. 13, 2024
Rev Recd Date: Aug. 24, 2024
Publish Date: Sep. 19, 2024

Abstract

Abstract

Diabetes mellitus (DM) is a major metabolic disease endangering global health, with diabetic nephropathy (DN) as a primary complication lacking curative therapy. Sporoderm-broken spores of Ganoderma lucidum (GLP), an herbal medicine, has been used for the treatment of metabolic disorders. In this study, DN was induced in Sprague-Dawley rats using streptozotocin (STZ) and a high-fat diet (HFD), and the protective mechanisms of GLP were investigated through transcriptomic, metabolomic, and network pharmacology (NP) analyses. Our results demonstrated that GLP intervention ameliorated renal damage and inflammation levels in DN rats. Integrative metabolomic and transcriptomic analysis revealed that GLP treatment modulated glucose and cellular energy metabolisms by regulating relevant genes. GLP significantly suppressed the inflammations by impacting glucose and energy metabolism-related gene expression (Igfbp1 and Angptl4) and enhanced metabolic biomarkers of 4-Aminocatechol. In addition, NP analysis further indicated that GLP may efficiently alleviate DN via immune-related pathways. In conclusion, this study provides supportive evidence of the anti-inflammatory effects of GLP supplements, highlighting their potential for promising clinical applications in treating DN.
- Diabetic nephropathy,
- Metabolome,
- Network pharmacology,
- Sporoderm-broken spores of Ganoderma lucidum,
- Transcriptome

FullText(HTML)

References(50)

References

[1]	L. Chen, D.J. Magliano, P.Z. Zimmet, The worldwide epidemiology of type 2 diabetes mellitus: Present and future perspectives, Nat.Rev. Endocrinol. 8 (2011) 228-236.
[2]	F. Giacco, M. Brownlee, Oxidative stress and diabetic complications, Circ. Res. 107 (2010) 1058-1070.
[3]	B. Giri, S. Dey, T. Das, et al., Chronic hyperglycemia mediated physiological alteration and metabolic distortion leads to organ dysfunction, infection, cancer progression and other pathophysiological consequences: An update on glucose toxicity, Biomed. Pharmacother. 107 (2018) 306-328.
[4]	S. Huang, M. Tan, F. Guo, et al., Nepeta angustifolia C. Y. Wu improves renal injury in HFD/STZ-induced diabetic nephropathy and inhibits oxidative stress-induced apoptosis of mesangial cells, J. Ethnopharmacol. 255 (2020), 112771.
[5]	S. Zheng, D.W. Powell, F. Zheng, et al., Diabetic nephropathy: Proteinuria, inflammation, and fibrosis, J. Diabetes Res. 2016 (2016), 5241549.
[6]	Z. Li, Y. Shi, X. Zhang, et al., Screening immunoactive compounds of Ganoderma lucidum spores by mass spectrometry molecular networking combined with in vivo zebrafish assays, Front. Pharmacol. 11 (2020), 287.
[7]	J. Su, L. Su, D. Li, et al., Antitumor activity of extract from the sporoderm-breaking spore of Ganoderma lucidum: Restoration on exhausted cytotoxic T cell with gut microbiota remodeling, Front. Immunol. 9 (2018), 1765.
[8]	E. Ekiz, E. Oz, A.M. Abd El-Aty, et al., Exploring the potential medicinal benefits of Ganoderma lucidum: From metabolic disorders to coronavirus infections, Foods 12 (2023), 1512.
[9]	A.M. F, Ganoderma lucidum: Persuasive biologically active constituents and their health endorsement, Biomed. Pharmacother. 107 (2018) 507-519.
[10]	S. Cheng, D. Sliva, Ganoderma lucidum for cancer treatment: We are close but still not there, Integr. Cancer Ther. 14 (2015) 249-257.
[11]	R. Cui, F. Zhu, Ultrasound modified polysaccharides: A review of structure, physicochemical properties, biological activities and food applications, Trends Food Sci. Technol. 107 (2021) 491-508.
[12]	C. Gong, M.C. Lee, M. Godec, et al., Ultrasonic encapsulation of cinnamon flavor to impart heat stability for baking applications, Food Hydrocoll. 99 (2020), 105316.
[13]	Y. Wang, X. Fan, X. Wu, Ganoderma lucidum polysaccharide (GLP) enhances antitumor immune response by regulating differentiation and inhibition of MDSCs via a CARD9-NF-κB-IDO pathway, Biosci. Rep. 40 (2020), BSR20201170.
[14]	H. Zhao, Q. Zhang, L. Zhao, et al., Spore Powder of Ganoderma lucidum improves cancer-related fatigue in breast cancer patients undergoing endocrine therapy: A pilot clinical trial, Evid. Based Complement. Alternat. Med. 2012 (2012), 809614.
[15]	H.M. Akshay Kumar, M. Sarkar, K. Darshan, et al., The Ganoderma: Biodiversity and Significance. Fungal Biology. Springer Nature Singapore, 2022, pp. 255-291.
[16]	Y. Hu, S. Wang, F. Wu, et al., Effects and mechanism of Ganoderma lucidum polysaccharides in the treatment of diabetic nephropathy in streptozotocin-induced diabetic rats, BioMed Res. Int. 2022 (2022), 4314415.
[17]	C. Guo, D. Guo, L. Fang, et al., Ganoderma lucidum polysaccharide modulates gut microbiota and immune cell function to inhibit inflammation and tumorigenesis in colon, Carbohydr. Polym. 267 (2021), 118231.
[18]	X. Geng, D. Zhong, L. Su, et al., Preventive and therapeutic effect of Ganoderma lucidum on kidney injuries and diseases, Adv. Pharmacol. 87 (2020) 257-276.
[19]	M.F. Ahmad, F.A. Ahmad, N. Hasan, et al., Ganoderma lucidum: Multifaceted mechanisms to combat diabetes through polysaccharides and triterpenoids: A comprehensive review, Int. J. Biol. Macromol. 268 (2024), 131644.
[20]	H.M. Colhoun, M.L. Marcovecchio, Biomarkers of diabetic kidney disease, Diabetologia 61 (2018) 996-1011.
[21]	H. Wu, R. Gonzalez Villalobos, X. Yao, et al., Mapping the single-cell transcriptomic response of murine diabetic kidney disease to therapies, Cell Metab. 34 (2022) 1064-1078.e6.
[22]	F. Persson, P. Rossing, Diagnosis of diabetic kidney disease: State of the art and future perspective, Kidney Int. Suppl. 8 (2018) 2-7.
[23]	Y. Zhao, Y. Qin, X. Hu, et al., Sporoderm-removed Ganoderma lucidum spores ameliorated early depression-like behavior in a rat model of sporadic Alzheimer’s disease, Front. Pharmacol. 15 (2024), 1406127.
[24]	H. Zhao, S. Cui, Y. Qin, et al., Prophylactic effects of sporoderm-removed Ganoderma lucidum spores in a rat model of streptozotocin-induced sporadic Alzheimer’s disease, J. Ethnopharmacol. 269 (2021), 113725.
[25]	L. Xia, R. Sun, L. Zhang, et al., A 26-week repeated dose toxicity evaluation of sporoderm-removed Ganoderma lucidum spores in rats, Food Chem. Toxicol. 182 (2023), 114175.
[26]	K. Su, B. Yi, B. Yao, et al., Liraglutide attenuates renal tubular ectopic lipid deposition in rats with diabetic nephropathy by inhibiting lipid synthesis and promoting lipolysis, Pharmacol. Res. 156 (2020), 104778.
[27]	L. Zhu, J. Han, R. Yuan, et al., Berberine ameliorates diabetic nephropathy by inhibiting TLR4/NF-κB pathway, Biol. Res. 51 (2018), 9.
[28]	Y. Xiong, L. Zhou, The signaling of cellular senescence in diabetic nephropathy, Oxid. Med. Cell. Longev. 2019 (2019), 7495629.
[29]	S. Huang, Z. Ning, Extraction of polysaccharide from Ganoderma lucidum and its immune enhancement activity, Int. J. Biol. Macromol. 47 (2010) 336-341.
[30]	W. Zhang, Z. Lei, J. Meng, et al., Water extract of sporoderm-broken spores of Ganoderma lucidum induces osteosarcoma apoptosis and restricts autophagic flux, Onco. Targets Ther. 12 (2019) 11651-11665.
[31]	X. Jin, J. Ruiz Beguerie, D.M. Sze, et al., Ganoderma lucidum (Reishi mushroom) for cancer treatment, Cochrane Database Syst. Rev. 4 (2016), CD007731.
[32]	A. Barbieri, V. Quagliariello, V. del Vecchio, et al., Anticancer and anti-inflammatory properties of Ganoderma lucidum extract effects on melanoma and triple-negative breast cancer treatment, Nutrients 9 (2017), 210.
[33]	H.J. Janse van Rensburg, T. Azad, M. Ling, et al., The hippo pathway component TAZ promotes immune evasion in human cancer through PD-L1, Cancer Res. 78 (2018) 1457-1470.
[34]	L. Chen, X. Chen, X. Huang, et al., Regulation of glucose and lipid metabolism in health and disease, Sci. China Life Sci. 62 (2019) 1420-1458.
[35]	M. Alsahli, J.E. Gerich, Renal glucose metabolism in normal physiological conditions and in diabetes, Diabetes Res. Clin. Pract. 133 (2017) 1-9.
[36]	R. Fernandes, The controversial role of glucose in the diabetic kidney, Porto Biomed. J. 6 (2021), e113.
[37]	V.A. Ezzat, E.R. Duncan, S.B. Wheatcroft, et al., The role of IGF-I and its binding proteins in the development of type 2 diabetes and cardiovascular disease, Diabetes Obes. Metab. 10 (2008) 198-211.
[38]	T. Gu, H. Falhammar, H.F. Gu, et al., Epigenetic analyses of the insulin-like growth factor binding protein 1 gene in type 1 diabetes and diabetic nephropathy, Clin. Epigenetics 6 (2014), 10.
[39]	E. Al Shawaf, M. Abu-Farha, S. Devarajan, et al., ANGPTL4: A predictive marker for diabetic nephropathy, J. Diabetes Res. 2019 (2019), 4943191.
[40]	H.M. Hassan, Y.F. Mahran, A.M.H. Ghanim, Ganoderma lucidum ameliorates the diabetic nephropathy via down-regulatory effect on TGFβ-1 and TLR-4/NFκB signalling pathways, J. Pharm. Pharmacol. 73 (2021) 1250-1261.
[41]	J.F. Navarro-Gonzalez, C. Mora-Fernandez, The role of inflammatory cytokines in diabetic nephropathy, J. Am. Soc. Nephrol. 19 (2008) 433-442.
[42]	C. Xiao, Q. Wu, W. Cai, et al., Hypoglycemic effects of Ganoderma lucidum polysaccharides in type 2 diabetic mice, Arch. Pharm. Res. 35 (2012) 1793-1801.
[43]	S.W. Seto, T.Y. Lam, H.L. Tam, et al., Novel hypoglycemic effects of Ganoderma lucidum water-extract in obese/diabetic (+db/+db) mice, Phytomedicine 16 (2009) 426-436.
[44]	H. Xue, J. Qiao, G. Meng, et al., Effect of Ganoderma lucidum polysaccharides on hemodynamic and antioxidation in T2DM rats, Zhongguo Zhong Yao Za Zhi 35 (2010) 339-343.
[45]	C.J. Chang, C. Lin, C.C. Lu, et al., Ganoderma lucidum reduces obesity in mice by modulating the composition of the gut microbiota, Nat. Commun. 6 (2015), 7489.
[46]	S. Dudhgaonkar, A. Thyagarajan, D. Sliva, Suppression of the inflammatory response by triterpenes isolated from the mushroom Ganoderma lucidum, Int. Immunopharmacol. 9 (2009) 1272-1280.
[47]	C. Cheng, A.Y. Leung, C.F. Chen, The effects of two different Ganoderma species (Lingzhi) on gene expression in human monocytic THP-1 cells, Nutr. Cancer 62 (2010) 648-658.
[48]	J. Xie, D. Lin, J. Li, et al., Effects of Ganoderma lucidum polysaccharide peptide ameliorating cyclophosphamide-induced immune dysfunctions based on metabolomics analysis, Front. Nutr. 10 (2023), 1179749.
[49]	S. Zhang, G. Pang, C. Chen, et al., Effective cancer immunotherapy by Ganoderma lucidum polysaccharide-gold nanocomposites through dendritic cell activation and memory T cell response, Carbohydr. Polym. 205 (2019) 192-202.
[50]	G. Pang, S. Zhang, X. Zhou, et al., Immunoactive polysaccharide functionalized gold nanocomposites promote dendritic cell stimulation and antitumor effects, Nanomedicine (Lond) 14 (2019) 1291-1306.